The European Commission has given approval to a high-dose regimen of Spinraza (nusinersen) for people with 5q spinal muscular atrophy (SMA).

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and ...

Spinraza (nusinersen) is a brand-name drug that’s prescribed for spinal muscular atrophy (SMA) in adults and children. Spinraza comes as a spinal injection that’s given by a healthcare professional ...

A creatine loading phase is when a person takes a higher dose than the maintenance level for several days. Proponents suggest this saturates the muscles with creatine, allowing people to experience ...

New data from Biogen shows improved motor function in SMA patients using a higher dose of nusinersen, highlighting early treatment benefits. Biogen announced new data from the DEVOTE Part C and ...